These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8465275)

  • 1. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs.
    Iyer L; Shavit J; Koza M; Calabria R; Moran S; Fareed J
    Thromb Res; 1993 Jan; 69(1):59-70. PubMed ID: 8465275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
    Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
    Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
    Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
    Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
    Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
    Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.
    Meng M; Liu Y; Wang YB; Wang JC; Zhang H; Wang XQ; Zhang X; Lu WL; Zhang Q
    J Control Release; 2008 Jun; 128(2):113-9. PubMed ID: 18423766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes.
    Liu Y; Lu WL; Zhang X; Wang XQ; Zhang H; Zhang Q
    Peptides; 2005 Mar; 26(3):423-30. PubMed ID: 15652649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinico-pharmacological studies with recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J; Vogel G
    Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
    Kouz J; Czech J; Nicolay U; Dickneite G
    Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies.
    Zhang Y; Zhang Q; Sun Y; Sun J; Wang X; Chen M
    Biol Pharm Bull; 2005 Dec; 28(12):2263-7. PubMed ID: 16327162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacology of recombinant hirudin, a new anticoagulant.
    Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
    S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
    Berry CN; Girardot C; Lecoffre C; Lunven C
    Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
    Bichler J; Siebeck M; Fichtl B; Fritz H
    Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin effects of native and recombinant hirudins.
    Markwardt F; Stürzebecher J; Glusa E
    Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.
    Mo W; Zhang YL; Chen HS; Wang LS; Song HY
    J Thromb Thrombolysis; 2009 Aug; 28(2):230-7. PubMed ID: 18998199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological survey of recombinant hirudin.
    Markwardt F; Fink G; Kaiser B; Klöcking HP; Nowak G; Richter M; Stürzebecher J
    Pharmazie; 1988 Mar; 43(3):202-7. PubMed ID: 3380865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.